{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:21Z","timestamp":1753891221841,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> The mortality of invasive pulmonary aspergillosis (IPA) in patients with liver failure was high. However, the prophylactic treatment in those patients with a high-risk factor in IPA has not been researched.<\/jats:p><jats:p><jats:bold>Patients and methods:<\/jats:bold> A multicenter, retrospective study was conducted in patients with liver failure. The study cohort of liver failure was randomly split into a training set for model development and the other served as the testing set for model verification. Multivariate analysis was performed to identify the risk factors of IPA. A weighted risk score for IPA was established. Anti-fungal treatment was prophylactically used in patients with medium and high IPA risk to evaluate the effect.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 1,722 patients with liver failure were enrolled. Fifty-seven patients who received prophylactic treatment were excluded from the risk factor system study. About 1,665 patients were randomly split at a ratio of 2:1 into two datasets. Diabetes, glucocorticoids, plasma exchange, and hepatorenal syndrome (HRS) were risk factors in IPA in patients with liver failure, with weighted risk scores of 4, 7, 2, and 3, respectively. In the validation set and test set, the patients with risk scores of \u2264 3 presented low incidences of IPA at 4 and 2.7%. Patients with risk scores of 4\u20135 had an IPA incidence of 7.6% and 10.1%, and could be considered as a medium-risk group (<jats:italic>p<\/jats:italic> &amp;lt; 0.01 vs. the group with scores of \u2264 3), whereas those with risk scores of &amp;gt;5 manifested a significantly higher IPA incidence of 21.2 and 12.7%, who were considered a high-risk group (<jats:italic>p<\/jats:italic> &amp;lt; 0.01 vs. the groups with scores of 4\u20135 and &amp;gt;5, respectively). The IPA risk scores in the training set and the testing set were also analyzed by the ROC with an area under the ROC of 0.7152 and 0.6912. In this study, 57 patients received antifungal prophylaxis; the incidence of IPA was 1.8%, which was significantly lower after prophylactic antifungal therapy (<jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> A weighted risk score for patients with liver failure, complicated with IPA, was established and confirmed in the testing cohort. Voriconazole prophylactic treatment to patients with liver failure with medium and high IPA risk can effectively prevent Aspergillus infection.<\/jats:p>","DOI":"10.3389\/fmed.2021.762504","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T04:31:55Z","timestamp":1637555515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Risk Score for Invasive Pulmonary Aspergillosis in Patients With Liver Failure: A Retrospective Study in Zhejiang"],"prefix":"10.3389","volume":"8","author":[{"given":"Xuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiahong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjiao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hainv","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.7150\/ijms.6824","article-title":"Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study","volume":"10","author":"Chen","year":"2013","journal-title":"Int J Med Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/0300060517729907","article-title":"Epidemiology of invasive pulmonary aspergillosis in patients with liver failure: clinical presentation, risk factors, and outcomes","volume":"46","author":"Zhang","year":"2018","journal-title":"J Int Med Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/liv.13981","article-title":"Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections","volume":"39","author":"Verma","year":"2019","journal-title":"Liver Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41598-018-19320-2","article-title":"Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/S0140-6736:14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1177\/030006051204000537","article-title":"Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure","volume":"40","author":"Wu","year":"2012","journal-title":"J Int Med Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09059180.00001011","article-title":"Pulmonary aspergillosis: a clinical review","volume":"20","author":"Kousha","year":"2011","journal-title":"Eur Respir Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11684-018-0641-0","article-title":"Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study","volume":"13","author":"Wang","year":"2019","journal-title":"Front Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/ctr.12516","article-title":"Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis","volume":"29","author":"Chong","year":"2015","journal-title":"Clin Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3760\/cma.j.issn.1000-6680.2019.01.001","article-title":"Chinese Medical Association. Diagnositic and treatment guidelines for liver failure","volume":"37","year":"2019","journal-title":"Chinese Journal of Infectious Diseases."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/QCO.0000000000000043","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti","year":"2014","journal-title":"Curr Opin Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10096-010-1137-2","article-title":"Invasive pulmonary aspergillosis in patients with HBV-related liver failure","volume":"30","author":"Wang","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1038\/s41598-019-48183-4","article-title":"Prevalence and outcome of invasive pulmonary aspergillosis in critically ill patients with liver cirrhosis: an observational study","volume":"9","author":"Lahmer","year":"2019","journal-title":"Sci Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3748\/wjg.v26.i2.219","article-title":"Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review","volume":"26","author":"Tan","year":"2020","journal-title":"World J Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2015.08.018","article-title":"High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial","volume":"64","author":"Larsen","year":"2016","journal-title":"J Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"Wendon","year":"2017","journal-title":"J Hepatol"},{"key":"B21","first-page":"344","article-title":"Investigation of interleukin-10, tumor necrosis factor-alpha and interferon-gamma expression in experimental model of pulmonary aspergillosis","volume":"45","author":"Caglar","year":"2011","journal-title":"Mikrobiyol Bul."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/bcp.13595","article-title":"Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients","volume":"84","author":"Lin","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000509970","article-title":"A prospective study on the usefulness of initial voriconazole dose adjustment based on CYP2C19 gene polymorphism analysis","volume":"65","author":"Tanaka","year":"2020","journal-title":"Chemotherapy"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.762504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T04:32:00Z","timestamp":1637555520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.762504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":23,"alternative-id":["10.3389\/fmed.2021.762504"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.762504","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"article-number":"762504"}}